Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Cost of Revenue (2021 - 2024)

Goldenwell Biotech (GWLL) has disclosed Cost of Revenue for 4 consecutive years, with $6.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cost of Revenue fell 96.79% year-over-year to $6.0, compared with a TTM value of $6.0 through Sep 2025, down 97.66%, and an annual FY2024 reading of $75.0, down 93.59% over the prior year.
  • Cost of Revenue was $6.0 for Q4 2024 at Goldenwell Biotech, down from $69.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $20663.0 in Q3 2022 and bottomed at -$1951.0 in Q4 2022.
  • Average Cost of Revenue over 4 years is $2273.0, with a median of $196.0 recorded in 2023.
  • The sharpest move saw Cost of Revenue tumbled 252.54% in 2022, then soared 278.19% in 2023.
  • Year by year, Cost of Revenue stood at $1279.0 in 2021, then crashed by 252.54% to -$1951.0 in 2022, then soared by 109.58% to $187.0 in 2023, then crashed by 96.79% to $6.0 in 2024.
  • Business Quant data shows Cost of Revenue for GWLL at $6.0 in Q4 2024, $69.0 in Q2 2024, and $187.0 in Q4 2023.